Literature DB >> 24660051

An Accessible Chiral Linker to Enhance Potency and Selectivity of Neuronal Nitric Oxide Synthase Inhibitors.

Qing Jing1, Huiying Li2, Linda J Roman3, Pavel Martásek4, Thomas L Poulos2, Richard B Silverman1.   

Abstract

The three important mammalian isozymes of nitric oxide synthase (NOS) are neuronal NOS (nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS). Inhibitors of nNOS show promise as treatments for neurodegenerative diseases. Eight easily-synthesized compounds containing either one (20a,b) or two (9a-d; 15a,b) 2-amino-4-methylpyridine groups with a chiral pyrrolidine linker were designed as selective nNOS inhibitors. Inhibitor 9c is the best of these compounds, having a potency of 9.7 nM and dual selectivity of 693 and 295 against eNOS and iNOS, respectively. Crystal structures of nNOS complexed with either 9a or 9c show a double-headed binding mode, where each 2-aminopyridine head group interacts with either a nNOS active site Glu residue or a heme propionate. In addition, the pyrrolidine nitrogen of 9c contributes additional hydrogen bonds to the heme propionate, resulting in a unique binding orientation. In contrast, the lack of hydrogen bonds from the pyrrolidine of 9a to the heme propionate allows the inhibitor to adopt two different binding orientations. Both 9a and 9c bind to eNOS in a single-headed mode, which is the structural basis for the isozyme selectivity.

Entities:  

Keywords:  enzyme inhibition; neurodegenerative diseases; nitric oxide; nitric oxide synthase

Year:  2014        PMID: 24660051      PMCID: PMC3960082          DOI: 10.1021/ml400381s

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  16 in total

1.  Applications of organocatalytic asymmetric synthesis to drug prototypes--dual action and selective inhibitors of n-nitric oxide synthase with activity against the 5-HT1D/1B subreceptors.

Authors:  Stephen Hanessian; Eli Stoffman; Xueling Mi; Paul Renton
Journal:  Org Lett       Date:  2011-01-27       Impact factor: 6.005

2.  Symmetric double-headed aminopyridines, a novel strategy for potent and membrane-permeable inhibitors of neuronal nitric oxide synthase.

Authors:  Fengtian Xue; Jianguo Fang; Silvia L Delker; Huiying Li; Pavel Martásek; Linda J Roman; Thomas L Poulos; Richard B Silverman
Journal:  J Med Chem       Date:  2011-03-16       Impact factor: 7.446

Review 3.  Role of nitric oxide in Parkinson's disease.

Authors:  Li Zhang; Valina L Dawson; Ted M Dawson
Journal:  Pharmacol Ther       Date:  2005-07-07       Impact factor: 12.310

Review 4.  Design of isoform-selective inhibitors of nitric oxide synthase.

Authors:  B R Babu; O W Griffith
Journal:  Curr Opin Chem Biol       Date:  1998-08       Impact factor: 8.822

5.  Design, synthesis, and biological evaluation of 3,4-dihydroquinolin-2(1H)-one and 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors.

Authors:  Jailall Ramnauth; Joanne Speed; Shawn P Maddaford; Peter Dove; Subhash C Annedi; Paul Renton; Suman Rakhit; John Andrews; Sarah Silverman; Gabriela Mladenova; Salvatore Zinghini; Sheela Nair; Concettina Catalano; David K H Lee; Milena De Felice; Frank Porreca
Journal:  J Med Chem       Date:  2011-07-08       Impact factor: 7.446

Review 6.  Mitochondrial contributions to tissue damage in stroke.

Authors:  Neil R Sims; Michelle F Anderson
Journal:  Neurochem Int       Date:  2002-05       Impact factor: 3.921

Review 7.  Nitric oxide synthase inhibitors for the treatment of chronic tension-type headache.

Authors:  Messoud Ashina
Journal:  Expert Opin Pharmacother       Date:  2002-04       Impact factor: 3.889

8.  Structural basis for isoform-selective inhibition in nitric oxide synthase.

Authors:  Thomas L Poulos; Huiying Li
Journal:  Acc Chem Res       Date:  2012-10-02       Impact factor: 22.384

Review 9.  Design of selective neuronal nitric oxide synthase inhibitors for the prevention and treatment of neurodegenerative diseases.

Authors:  Richard B Silverman
Journal:  Acc Chem Res       Date:  2009-03-17       Impact factor: 22.384

10.  Decreased neuronal nitric oxide synthase messenger RNA and somatostatin messenger RNA in the striatum of Huntington's disease.

Authors:  P J Norris; H J Waldvogel; R L Faull; D R Love; P C Emson
Journal:  Neuroscience       Date:  1996-06       Impact factor: 3.590

View more
  6 in total

1.  Nω-NITRO-Nω'-SUBSTITUTED GUANIDINES: A SIMPLE CLASS OF NITRIC OXIDE SYNTHASE INHIBITORS.

Authors:  Christophe D Guillon; David D Wisnoski; Jaya Saxena; Ned D Heindel; Diane E Heck; Donald J Wolff; Jeffrey D Laskin
Journal:  Mod Res Inflamm       Date:  2014-05

2.  Inhibitor Bound Crystal Structures of Bacterial Nitric Oxide Synthase.

Authors:  Jeffrey K Holden; Dillon Dejam; Matthew C Lewis; He Huang; Soosung Kang; Qing Jing; Fengtian Xue; Richard B Silverman; Thomas L Poulos
Journal:  Biochemistry       Date:  2015-06-23       Impact factor: 3.162

3.  Combination of chiral linkers with thiophenecarboximidamide heads to improve the selectivity of inhibitors of neuronal nitric oxide synthase.

Authors:  Qing Jing; Huiying Li; Linda J Roman; Pavel Martásek; Thomas L Poulos; Richard B Silverman
Journal:  Bioorg Med Chem Lett       Date:  2014-08-12       Impact factor: 2.823

Review 4.  Nitric oxide synthase and structure-based inhibitor design.

Authors:  Thomas L Poulos; Huiying Li
Journal:  Nitric Oxide       Date:  2016-11-23       Impact factor: 4.427

5.  Structures of human constitutive nitric oxide synthases.

Authors:  Huiying Li; Joumana Jamal; Carla Plaza; Stephanie Hai Pineda; Georges Chreifi; Qing Jing; Maris A Cinelli; Richard B Silverman; Thomas L Poulos
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2014-09-27

6.  The mobility of a conserved tyrosine residue controls isoform-dependent enzyme-inhibitor interactions in nitric oxide synthases.

Authors:  Huiying Li; Joumana Jamal; Silvia Delker; Carla Plaza; Haitao Ji; Qing Jing; He Huang; Soosung Kang; Richard B Silverman; Thomas L Poulos
Journal:  Biochemistry       Date:  2014-08-11       Impact factor: 3.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.